Medical Care |

Medical Care

##SEVER##

/s/sustc-genome.org.cn1.html

Vp drug response report

VP Genetic Results
Prepared for: sample1 VP: Virtual Pharmacist
VP established researrch report
User account: sample1
Efavirenz
For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or
tenofovir is the preferred NNRTI-based regimen.
Your genetic data
For a list of references for each variant, please see the freely available VP on the Internet https://www.sustc-genome.org.cn/vp The description of rs3745274
Patients with the GT genotype may have an increased risk of efavirenz-induced side effects (central nervous
symptoms, fatigue, sleep disorder, liver toxicity or early termination of drug therapy) as compared to patients with
the GG genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.
Jiankui He Lab, Department of Biology, South University of Science and Technology of China VP: Virtual Pharmacist
VP established researrch report
User account: sample1
Ribavirin
A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and
DNA viruses. [PubChem]
Your genetic data
For a list of references for each variant, please see the freely available VP on the Internet https://www.sustc-genome.org.cn/vp The description of rs12979860
Patients with the TT genotype may have decreased response to peginterferon alpha and ribavirin in people with
Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the TT genotype may also
have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and
clinical factors may also influence a patients response to peginterferon.
The description of rs8099917
Patients with the GG genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin
therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical
factors may also influence a patients response to peginterferon alfa and ribavirin therapy.
Jiankui He Lab, Department of Biology, South University of Science and Technology of China VP: Virtual Pharmacist
VP established researrch report
User account: sample1
Antineoplastic agents
Inhibiting or preventing development of neoplasms; checking maturation and proliferation of malignant cells
Your genetic data
For a list of references for each variant, please see the freely available VP on the Internet https://www.sustc-genome.org.cn/vp The description of rs1042522
Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with
antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also
influence a patients response to antineoplastic agents.
Jiankui He Lab, Department of Biology, South University of Science and Technology of China VP: Virtual Pharmacist
VP established researrch report
User account: sample1
Capecitabine(FDA pharmacogenomic biomarker)
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and
colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the
tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Your genetic data
For a list of references for each variant, please see the freely available VP on the Internet https://www.sustc-genome.org.cn/vp The description of rs2297595
Patients with the CC genotype may have increased risk of severe toxicity when treated with fluoropyrimidines as
compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance
of adverse events.
Jiankui He Lab, Department of Biology, South University of Science and Technology of China VP: Virtual Pharmacist
VP established researrch report
User account: sample1
Carboplatin
An organoplatinum compound that possesses antineoplastic activity.
Your genetic data
For a list of references for each variant, please see the freely available VP on the Internet https://www.sustc-genome.org.cn/vp The description of rs1801133
Patients with AA genotype may have 1) increased likelihood of response 2) increased progression free survival to
carboplatin in people with Non-Small-Cell Lung Carcinoma as compared to patients with genotype AG or GG.
Other genetic and clinical factors may also influence a patients response to carboplatin.
Jiankui He Lab, Department of Biology, South University of Science and Technology of China VP: Virtual Pharmacist
VP established researrch report
User account: sample1
Celecoxib(FDA pharmacogenomic biomarker)
Celecoxib is a non-steroidal anti-inflammatory drug
Your genetic data
For a list of references for each variant, please see the freely available VP on the Internet https://www.sustc-genome.org.cn/vp The description of rs1799853
Patients with the CT genotype who are treated with celecoxib may have a decreased metabolism of celecoxib and
as compared to patients with the CC genotype. This association has been contradicted in some studies. Other
genetic and clinical factors may also influence a patients response to celecoxib.
Jiankui He Lab, Department of Biology, South University of Science and Technology of China VP: Virtual Pharmacist
VP established researrch report
User account: sample1
Cisplatin(FDA pharmacogenomic biomarker)
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to
treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian
cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin
and oxaliplatin.
Your genetic data
For a list of references for each variant, please see the freely available VP on the Internet https://www.sustc-genome.org.cn/vp The description of rs2228001
Patients with the TT genotype may have a decreased but not non-existent risk for toxicity with cisplatin treatment
as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a
patients risk for toxicity.
The description of rs1800460
Patients with the TC genotype and cancer who are treated with cisplatin may have an increased risk for hearing
loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients
risk for hearing loss with cisplatin treatment.
The description of rs1042522
Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with
antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also
influence a patients response to antineoplastic agents.
The description of rs1801133
Patients with the AA genotype may have: 1) increased likelihood of response to chemotherapy, 2) increased
likelihood of Drug Toxicity when treated with cisplatin in cancer patients as compared to patients with genotypes
AG or GG. Other genetic and clinical factors may also influence a patients response to cisplatin.
The description of rs1695
Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may
have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However,
Jiankui He Lab, Department of Biology, South University of Science and Technology of China VP: Virtual Pharmacist
VP established researrch report
User account: sample1
this association was contradicted in other studies. Other genetic and clinical factors may also influence a patientsresponse to cisplatin and cyclophosphamide treatment.
The description of rs1695
Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may
have a decreased progression free survival as compared to patients with the AA genotype. This association is
contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin
and cyclophosphamide.
The description of rs9332377
Patients with the CT genotype who are treated with cisplatin may have an increased risk of hearing loss as
compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for
hearing loss with cisplatin treatment.
Jiankui He Lab, Department of Biology, South University of Science and Technology of China VP: Virtual Pharmacist
VP established researrch report
User account: sample1
Cyclophosphamide
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in
the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side
effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects,
mutations, and cancer. [PubChem]
Your genetic data
For a list of references for each variant, please see the freely available VP on the Internet https://www.sustc-genome.org.cn/vp The description of rs1042522
Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with
antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also
influence a patients response to antineoplastic agents.
The description of rs1801133
Patients with the AA genotype may have increased likelihood of Drug Toxicity when treated with
cyclophosphamide as compared to patients with the GG or AG genotype. Other genetic and clinical factors may
also influence a patients risk of toxicity to cyclophosphamide.
The description of rs1695
Patients with the AG genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may
have 1) increased drug response 2) decreased severity of toxicity as compared to patients with GG genotype.
Some patients were additionally treated with fluorouracilOther genetic and clinical factors may influence a patients
response to cyclophosphamide, epirubicin and fluorouracil.
The description of rs1695
Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may
have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However,
this association was contradicted in other studies. Other genetic and clinical factors may also influence a patients
response to cisplatin and cyclophosphamide treatment.
The description of rs1695
Jiankui He Lab, Department of Biology, South University of Science and Technology of China VP: Virtual Pharmacist
VP established researrch report
User account: sample1
Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide mayhave a decreased progression free survival as compared to patients with the AA genotype. This association iscontradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatinand cyclophosphamide.
The description of rs3745274
Leukemia patients who are recipients of HLA-identical hematopoietic stem cell transplantation from donors with
the GT genotype may have a decreased risk of developing veno-occlusive disease of the liver when treated with
cyclophosphamide as compared to donor cells with the GG genotype. Other genetic and clinical factors may also
influence a patients risk for venoocclusive disease of the liver.
The description of rs3745274
Patients with the GT genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may
be more likely to require a reduction in dose as compared to patients with the TT genotype, or may be less likely to
require a reduction in dose as compared to patients with the GG genotype. Other genetic and clinical factors may
also influence a patients dose requirements.
Jiankui He Lab, Department of Biology, South University of Science and Technology of China VP: Virtual Pharmacist
VP established researrch report
User account: sample1
Epirubicin
The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
Your genetic data
For a list of references for each variant, please see the freely available VP on the Internet https://www.sustc-genome.org.cn/vp The description of rs1695
Patients with the AG genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may
have 1) increased drug response 2) decreased severity of toxicity as compared to patients with GG genotype.
Some patients were additionally treated with fluorouracilOther genetic and clinical factors may influence a patients
response to cyclophosphamide, epirubicin and fluorouracil.
Jiankui He Lab, Department of Biology, South University of Science and Technology of China VP: Virtual Pharmacist
VP established researrch report
User account: sample1
Fluorouracil(FDA pharmacogenomic biomarker)
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the
thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]
Your genetic data
For a list of references for each variant, please see the freely available VP on the Internet https://www.sustc-genome.org.cn/vp The description of rs1042522
Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with
antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also
influence a patients response to antineoplastic agents.
The description of rs1801133
Patients with the AA genotype may have increased risk of Drug Toxicity in cancer patients treated with fluorouracil-
based therapy as compared to patients with the GG genotype. However, conflicting finding of no-association for
this genotype has also been reported. Other genetic and clinical factors may also influence a patients risk of toxicity
to fluorouracil.
The description of rs1695
Patients with the AG genotype and cancer who are treated with fluorouracil may have a lower, but not absent, risk
of hematological toxicity as compared to patients with the AA genotype, or may have a higher risk of hematological
toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a
patients risk for hematological toxicity when exposed to fluorouracil.
The description of rs2297595
Patients with the CC genotype may have increased risk of severe toxicity when treated with fluoropyrimidines as
compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance
of adverse events.
Jiankui He Lab, Department of Biology, South University of Science and Technology of China VP: Virtual Pharmacist
VP established researrch report
User account: sample1
Mercaptopurine(FDA pharmacogenomic biomarker)
An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis
by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in
remission maintenance programs for leukemia. [PubChem]
Your genetic data
For a list of references for each variant, please see the freely available VP on the Internet https://www.sustc-genome.org.cn/vp The description of rs1800460
Patients with the CT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues
as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk
for toxicity.
The description of rs1800462
Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an
increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other
genetic and clinical factors may also influence a patients risk for toxicity.
The description of rs1801133
Patients with the AA genotype may have increased likelihood of treatment interruptions when treated with
mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with
genotype GG. However, contradictory finding has been reported. Other genetic and clinical factors may also
influence a patients risk for toxicity to mercaptopurine.
Jiankui He Lab, Department of Biology, South University of Science and Technology of China VP: Virtual Pharmacist
VP established researrch report
User account: sample1
Methotrexate
An antineoplastic antimetabolite with immunosuppressant properties.
Your genetic data
For a list of references for each variant, please see the freely available VP on the Internet https://www.sustc-genome.org.cn/vp The description of rs1801133
Patients with the AA genotype with Leukemia or Lymphoma who are treated with methotrexate regimens may
have an increased risk and increased severity of mucositis, as compared to patients with the GA or GG genotype.
Other genetic and clinical factors may also influence a patients risk of oral mucositis.
The description of rs1801133
Patients with the AA genotype and Arthritis who are treated with methotrexate may have an increased risk of
adverse events and toxicity as compared to patients with the GG genotype (though this association has not been
found in all studies). There does not seem to be an association between this genotype and response to
methotrexate treatment. Other genetic and clinical factors may also influence a patients risk for adverse events with
methotrexate treatment.
The description of rs1801133
Patients with the AA genotype and non-Hodgkin lymphoma who are treated with methotrexate may have an
increased risk of mucositis, thrombocytopenia and hepatic toxicity as compared to patients with the GG genotype.
This association was not found in pediatric patients with non-Hodgkin lymphoma who were treated with
methotrexate. Other genetic and clinical factors may also influence a patients risk for methotrexate-induced toxicity.
The description of rs1801133
Patients with the AA genotype with non-hodgkin lymphoma who are treated with methotrexate may be less likely
to have event free survival at 5 years as compared to patients with the GG genotype. This genotype was not
associated with treatment outcome in pediatric patients with non-hodgkin lymphoma as compared to the GG
genotype. Other genetic and clinical factors may also influence a patients response to methotrexate treatment.
The description of rs1801133
Patients with the AA genotype and Leukemia who are treated with methotrexate: 1) may have poorer response to
treatment 2) may be at increased risk of toxicity 3) may require a lower dose of methotrexate as compared to
patients with the GG genotype. This association has been contradicted or not found in several studies. Other
Jiankui He Lab, Department of Biology, South University of Science and Technology of China VP: Virtual Pharmacist
VP established researrch report
User account: sample1
genetic and clinical factors may also influence a patients risk for toxicity and response with methotrexate treatment.
The description of rs1801133
Patients with the AA genotype and leukemia who undergo hematopoietic cell transplant and are treated with
methotrexate may have a decreased risk of Graft vs Host disease as compared to patients with the GG genotype.
Other genetic and clinical factors may also influence a patients risk Graft vs Host disease and efficacy of
methotrexate treatment.
Jiankui He Lab, Department of Biology, South University of Science and Technology of China VP: Virtual Pharmacist
VP established researrch report
User account: sample1
Oxaliplatin
Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically
administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of
colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved
antitumour activity.
Your genetic data
For a list of references for each variant, please see the freely available VP on the Internet https://www.sustc-genome.org.cn/vp The description of rs1695
Patients with the AG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a
decreased, but not absent, risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of
treatment as compared to patients with the AA genotype. Conflicting data exist for the neurotoxicity risk showing
that patients with the AG might have an increased risk. Other genetic and clinical factors may also influence a
patients risk for adverse events with oxaliplatin or platinum compounds treatment.
Jiankui He Lab, Department of Biology, South University of Science and Technology of China VP: Virtual Pharmacist
VP established researrch report
User account: sample1
Paclitaxel
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their
polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon
paclitaxel, one of the leading chemotherapy treatments.
Your genetic data
For a list of references for each variant, please see the freely available VP on the Internet https://www.sustc-genome.org.cn/vp The description of rs1042522
Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with
antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also
influence a patients response to antineoplastic agents.
Jiankui He Lab, Department of Biology, South University of Science and Technology of China VP: Virtual Pharmacist
VP established researrch report
User account: sample1
Thioguanine(FDA pharmacogenomic biomarker)
An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute
leukemia.
Your genetic data
For a list of references for each variant, please see the freely available VP on the Internet https://www.sustc-genome.org.cn/vp The description of rs1800460
Patients with the CT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues
as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk
for toxicity.
The description of rs1800462
Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an
increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other
genetic and clinical factors may also influence a patients risk for toxicity.
Jiankui He Lab, Department of Biology, South University of Science and Technology of China VP: Virtual Pharmacist
VP established researrch report
User account: sample1
Azathioprine(FDA pharmacogenomic biomarker)
An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine
metabolism and DNA synthesis.
Your genetic data
For a list of references for each variant, please see the freely available VP on the Internet https://www.sustc-genome.org.cn/vp The description of rs1800460
Patients with the CT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues
as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk
for toxicity.
The description of rs1800462
Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an
increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other
genetic and clinical factors may also influence a patients risk for toxicity.
Jiankui He Lab, Department of Biology, South University of Science and Technology of China VP: Virtual Pharmacist
VP established researrch report
User account: sample1
Phenprocoumon
Coumarin derivative that acts as a long acting oral anticoagulant. [PubChem]
Your genetic data
For a list of references for each variant, please see the freely available VP on the Internet https://www.sustc-genome.org.cn/vp The description of rs2108622
Patients with the TT genotype who are taking an oral anticoagulant may require the highest dose as compared to
patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients required dose.
Jiankui He Lab, Department of Biology, South University of Science and Technology of China VP: Virtual Pharmacist
VP established researrch report
User account: sample1
Warfarin(FDA pharmacogenomic biomarker)
Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although
originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently
prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used
medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding,
spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis,
purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been
documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k
dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.
Your genetic data
For a list of references for each variant, please see the freely available VP on the Internet https://www.sustc-genome.org.cn/vp The description of rs7294
Patients with the CT genotype who are treated with warfarin may require a higher dose as compared to patients
with the CC genotype.
The description of rs2108622
Patients with the TT genotype who are taking an oral anticoagulant may require the highest dose as compared to
patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients required dose.
The description of rs1799853
Patients with the CT genotype who are treated with warfarin may require a lower dose as compared to patients
with the CC genotype. Other genetic and clinical factors may also influence a patients dose of warfarin.
Jiankui He Lab, Department of Biology, South University of Science and Technology of China VP: Virtual Pharmacist
VP established researrch report
User account: sample1
Phenytoin(FDA pharmacogenomic biomarker)
An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The
mechanism of therapeutic action is not clear, although several cellular actions have been described including
effects on ion channels, active transport, and general membrane stabilization.
Your genetic data
For a list of references for each variant, please see the freely available VP on the Internet https://www.sustc-genome.org.cn/vp The description of rs1799853
Patients with the CT genotype and Epilepsy who are treated with phenytoin may have a decreased metabolism of
phenytoin, increased plasma free phenytoin concentration, and an increased risk of drug toxicity as compared to
patients with the CC genotype. These associations have been contradicted in some studies. Other genetic and
clinical factors may also influence a patients response to phenytoin.
Jiankui He Lab, Department of Biology, South University of Science and Technology of China VP: Virtual Pharmacist
VP established researrch report
User account: sample1
Ace inhibitors, plain
An ACE inhibitor (or angiotensin-converting-enzyme inhibitor) is a pharmaceutical drug used primarily for the
treatment of hypertension (elevated blood pressure) and congestive heart failure.
Your genetic data
For a list of references for each variant, please see the freely available VP on the Internet https://www.sustc-genome.org.cn/vp The description of rs11209716
Patients with the CC genotype and hypertension who are treated with ACE inhibitors may have a decreased, but
not absent, risk of cough as compared to patients with the TT genotype. Other genetic and clinical factors may also
influence a patients risk of cough when treated with ACE inhibitors.
The description of rs2016848
Patients with the AA genotype who are treated with ACE inhibitors may have an increased risk for cough as
compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for
cough with ACE inhibitor treatment.
Jiankui He Lab, Department of Biology, South University of Science and Technology of China VP: Virtual Pharmacist
VP established researrch report
User account: sample1
Acenocoumarol
Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist (like warfarin). It is a derivative of
coumarin and is marketed under the brand names Sintrom and Sinthrome.
Your genetic data
For a list of references for each variant, please see the freely available VP on the Internet https://www.sustc-genome.org.cn/vp The description of rs2108622
Patients with the TT genotype who are taking an oral anticoagulant may require the highest dose as compared to
patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients required dose.
Jiankui He Lab, Department of Biology, South University of Science and Technology of China VP: Virtual Pharmacist
VP established researrch report
User account: sample1
Anthracyclines and related substances
These compounds are used to treat many cancers, including leukemias, lymphomas, breast, uterine, ovarian, and
lung cancers.
Your genetic data
For a list of references for each variant, please see the freely available VP on the Internet https://www.sustc-genome.org.cn/vp The description of rs1056892
Patients with the AA genotype may have decreased risk of cardiac damage after anthracycline exposure as
compared to patients with the GG genotype. Patients with the AA genotype may still be at risk for adverse events
when exposed to anthracyclines based on their genotype. Other genetic and clinical factors may also influence a
patients risk for adverse events.
Jiankui He Lab, Department of Biology, South University of Science and Technology of China VP: Virtual Pharmacist
VP established researrch report
User account: sample1
Antipsychotics
Antipsychotics (also known as neuroleptics or major tranquilizers)[1] are a class of psychiatric medication primarily
used to manage psychosis (including delusions, hallucinations, or disordered thought), in particular in
schizophrenia and bipolar disorder, and is increasingly being used in the management of non-psychotic disorders
(ATC code N05A).
Your genetic data
For a list of references for each variant, please see the freely available VP on the Internet https://www.sustc-genome.org.cn/vp The description of rs1801133
Patients with the AA genotype treated with antipsychotics may have increased risk for metabolic syndrome as
compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for
adverse events.
Jiankui He Lab, Department of Biology, South University of Science and Technology of China VP: Virtual Pharmacist
VP established researrch report
User account: sample1
Nitrous oxide
Nitrous oxide, commonly known as laughing gas, nitrous, nitro, or NOS[1] is a chemical compound
Your genetic data
For a list of references for each variant, please see the freely available VP on the Internet https://www.sustc-genome.org.cn/vp The description of rs1801133
Patients with the AA genotype who undergo elective surgery with nitrous oxide anesthesia may have higher
plasma total homocysteine concentrations as compared to patients with the GG genotype. Other genetic and
clinical factors may also influence a patients homocysteine levels after nitrous oxide anesthesia.
Jiankui He Lab, Department of Biology, South University of Science and Technology of China VP: Virtual Pharmacist
VP established researrch report
User account: sample1
Peginterferon alfa-2a
Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an
antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both
antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known
as pegylation, enhances the half-life of the interferon when compared to its native form.
Your genetic data
For a list of references for each variant, please see the freely available VP on the Internet https://www.sustc-genome.org.cn/vp The description of rs12979860
Patients with the TT genotype may have decreased response to peginterferon alpha and ribavirin in people with
Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the TT genotype may also
have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and
clinical factors may also influence a patients response to peginterferon.
The description of rs8099917
Patients with the GG genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin
therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical
factors may also influence a patients response to peginterferon alfa and ribavirin therapy.
Jiankui He Lab, Department of Biology, South University of Science and Technology of China VP: Virtual Pharmacist
VP established researrch report
User account: sample1
Peginterferon alfa-2b(FDA pharmacogenomic biomarker)
Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an
antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both
antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known
as pegylation, enhances the half-life of the interferon when compared to its native form.
Your genetic data
For a list of references for each variant, please see the freely available VP on the Internet https://www.sustc-genome.org.cn/vp The description of rs12979860
Patients with the TT genotype may have decreased response to peginterferon alpha and ribavirin in people with
Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the TT genotype may also
have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and
clinical factors may also influence a patients response to peginterferon.
The description of rs8099917
Patients with the GG genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin
therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical
factors may also influence a patients response to peginterferon alfa and ribavirin therapy.
Jiankui He Lab, Department of Biology, South University of Science and Technology of China VP: Virtual Pharmacist
VP established researrch report
User account: sample1
Your genetic data
For a list of references for each variant, please see the freely available VP on the Internet https://www.sustc-genome.org.cn/vp The description of rs1695
Patients with the AG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a
decreased, but not absent, risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of
treatment as compared to patients with the AA genotype. Conflicting data exist for the neurotoxicity risk showing
that patients with the AG might have an increased risk. Other genetic and clinical factors may also influence a
patients risk for adverse events with oxaliplatin or platinum compounds treatment.
Jiankui He Lab, Department of Biology, South University of Science and Technology of China VP: Virtual Pharmacist
VP established researrch report
User account: sample1
Purine analogues
Purine analogues are antimetabolites that mimic the structure of metabolic purines. Including Mercaptopurine,
Thioguanine, Fludarabine
Your genetic data
For a list of references for each variant, please see the freely available VP on the Internet https://www.sustc-genome.org.cn/vp The description of rs1800460
Patients with the CT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues
as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk
for toxicity.
The description of rs1800462
Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an
increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other
genetic and clinical factors may also influence a patients risk for toxicity.
Jiankui He Lab, Department of Biology, South University of Science and Technology of China VP: Virtual Pharmacist
VP established researrch report
User account: sample1
The overview of VP
VP which is developed by He lab in the South University of Science and Technology of China is an online tool that
interprets personal genome for the impact of genetic variation on drug response. Base on the carefully selected
data from international and authoritative includinig PharmGKB, dbSNP and DrugBank?we can take high-throughput
sequencing raw data or microarray SNP genotyping data as inputs, and reports to the users how the variants in
their personal genomes impact the response to 193 drugs, including efficacy, dosage and toxicity.

Source: http://www.sustc-genome.org.cn/vp/download2.php?code=example&file=1

Microsoft word - 7thwribposterlist

7th Workshop on Recent Issues in Bioanalysis Poster List Tuesday April 9 Posters Poster T01: "Validation of a Dried Blood Spot Boanalytical Method for Perampanel Analysis in Pediatric Studies" Poster Presenter: Dr. Luca Matassa (Eisai, Woodcliff Lake, NJ, USA) Introduction: Perampanel is a first-in-class, orally administered, highly selective non-competitive AMPA-type glutamate receptor antagonist, developed by EISAI for epilepsy. A DBS-LC-MS/MS method has been developed and validated in order to analyse perampanel in heparinised blood samples from paediatric studies. Dried blood spots (DBS) have been shown to be a useful means of collecting, storing and shipping blood samples for quantitative drug analysis which provides advantages over conventional plasma collection. Moreover, due to low sample volume that DBS uses, it is a method of choice when it is comes to paediatric studies. Methods: A 20 uL dried blood spot on FTA DMPK A card is punched (6mm punch) and the subsample is solubilized by shaking in 150 uL of 90/10 methanol water containing internal standard (IS) stable label peramapanel. An aliquot of the solution is diluted with an equal volume of 50/50 methanol/water, centrifuged at 4C for 5 min prior to injecting 10uL on a reverse phase column (Chromolith RP18e 100x3mm) at 40C under gradient conditions. The detector was a Sciex API5500 Qtrap operated in positive ion ionspray mode. Quantitation was achieved monitoring precursor/product ions for analyte and IS (350/219 m/z perampanel; 356/219 IS) at retention time 2.5 minutes using 1/x2 linear weighted regression. Result: A full validation according to FDA and EMA guidance was conducted in human blood. Assay linearity was demonstrated over 7 validation runs with R-squared greater than 0.995. The intra-run accuracy and precision was between 95.2 -107.6% and 3.1-12.6%, respectively, at four concentration levels (LLQ, low QC, mid QC, high QC) demonstrating the repeatability of the analytical method from 1 to 500 ng/mL. The matrix factor in 6 lots of control blood was 1.0 for analyte and IS. Control blank matrix showed no interference at the LLQ. Punch tool carryover and autoinjector carryover were not found to impact assay performance. Analyte and IS recovery was 80% across all 3 QC levels with imprecision less than 5%. A 2-fold dilution factor was validated. The specificity of the method for perampanel at the LLOQ in presence of 10 other commonly used AEDs, individual y or pooled all together, (valproic acid, phenobarbital, lamotrigine, topiramate, oxcarbazepine, carbamazepine, levetiracetam, zonisamide, phenytoin, primidone) was demonstrated. A blood/plasma ratio of 0.88 was determined, allowing the correlation between blood and previous study plasma results. Short term autosample perampanel extract stability and perampanel stability in blood was demonstrated. Perampanel long term stability on DBS was demonstrated for 363 days at room temperature. Novel Aspect / Conclusion: The fully validated DBS-LC-MS/MS method was successfully applied to analysis of paediatric study clinical samples. Poster T02: "Unexpected Results for Sample Col ection and Handling Stability Assessment for Sumatriptan in Human Plasma" Poster Presenter: Ginny James (Celerion, Lincoln, Nebraska, USA) Introduction: Determination of sample col ection and handling stability (SCHS) is a requirement for validation of bioanalytical methods. SCHS of sumatriptan for 120 minutes did not meet pre-defined acceptance criteria. As sumatriptan was stable in plasma for 23 hours at ambient temperature, it was hypothesized that partitioning of sumatriptan between plasma and red blood cells was not immediate and was impacting the results of the early time points. Methods: Whole blood was fortified with sumatriptan at 0.150 and 100 ng/mL for target plasma concentrations of approximately 0.300 and 200 ng/mL. The samples were incubated in an ice-water bath, at ambient temperature, and at 37°C for multiple time points between 0 and 120 minutes. At each time point, samples were centrifuged, and the plasma layer was immediately frozen at -20°C. For samples in an ice-water bath for 30 minutes, the red cell fraction was also stored at -20°C for testing. The collected plasma samples were analyzed using a validated method for the quantitation of sumatriptan in human plasma. Red blood cel s were analyzed with the same chromatographic and instrument conditions after a protein crash of the cellular material.

Transformer in ceratitis

Development 129, 3715-3725 (2002) Printed in Great Britain © The Company of Biologists Limited 2002DEV7952 The transformer gene in Ceratitis capitata provides a genetic basis for selecting and remembering the sexual fate Attilio Pane, Marco Salvemini, Pasquale Delli Bovi, Catello Polito and Giuseppe Saccone* Dipartimento di Genetica, Biologia Generale e Molecolare, Università degli Studi di Napoli ‘Federico II', Via Mezzocannone 8,80134 Napoli, Italy*Author for correspondence (e-mail: saccone@biol.dgbm.unina.it)